VolitionRx Limited Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps ...

Innate Pharma (IPHA) announced the first patient was dosed in its Phase 1 study, investigating the safety and tolerability of IPH4502, an ...

Innate Pharma (NASDAQ:IPHA – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including ...

On Friday, H.C. Wainwright reaffirmed its Buy rating and $25.00 price target on shares of Innate Pharma (EPA:IPH) S.A. (NASDAQ:IPHA), currently trading at $1.67, following the company's ...

MARSEILLE, France, January 21, 2025--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will host an event for institutional ...

MARSEILLE, France, December 09, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced new data highlighting the quality-of-life ...

The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal cells unharmed.